-
DE
Cagrilintide is a long-acting amylin analogue under investigation for the treatment of obesity and type 2 diabetes, reducing appetite and regulating blood sugar levels.
Regular tips about health Regular tips about health Add as Preferred SourceCagrilintide is a long-acting amylin analogue under investigation for the treatment of obesity and type 2 diabetes, reducing appetite and regulating blood sugar levels.
Cagrilintide is an investigational, long-acting amylin analogue -- a synthetic peptide hormone structurally similar to the naturally occurring hormone amylin (also known as Islet Amyloid Polypeptide, or IAPP). Amylin is co-secreted with insulin by the beta cells of the pancreas and plays a key role in regulating blood glucose levels and satiety. Cagrilintide is being developed by the Danish pharmaceutical company Novo Nordisk and is currently being evaluated in clinical trials, including in combination with the GLP-1 receptor agonist semaglutide (under the project name CagriSema).
Cagrilintide is primarily being investigated for the following conditions:
Cagrilintide mimics the action of the natural hormone amylin by binding to amylin receptors in the brain and peripheral tissues. Its key pharmacological effects include:
Cagrilintide is administered as a subcutaneous injection (under the skin). In clinical trials, it is typically given once weekly, simplifying treatment for patients. Doses of up to 2.4 mg per week have been investigated in the SCALE trials and CagriSema combination studies. As the compound is still under clinical development, no officially approved standard dosage has yet been established.
Phase 2 and Phase 3 studies have shown promising results for cagrilintide:
As with other peptide hormone analogues, the most common side effects of cagrilintide are gastrointestinal in nature and include:
These side effects typically occur at the start of treatment and diminish over time in most patients. More serious adverse events, such as pancreatitis (inflammation of the pancreas), have been reported in association with amylin analogues and are being carefully monitored in ongoing trials.
Cagrilintide represents part of a new generation of combination therapies targeting obesity and type 2 diabetes. By simultaneously activating multiple hormonal pathways -- specifically the amylin and GLP-1 signalling axes -- this approach aims to achieve superior efficacy compared to single-agent treatments. If ongoing Phase 3 trials are successful, cagrilintide could be submitted for regulatory approval as part of a fixed-dose combination with semaglutide in the coming years.
As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.
Average rating of 4.97 out of 5 stars
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®
Average rating of 4.85 out of 5 stars
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
Average rating of 4.87 out of 5 stars
Daily basic supply: the complete spectrum of micronutrients
Natural multivitamin complex for the immune system, energy, and central body functions
Average rating of 4.94 out of 5 stars
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.